1,259 top medical experts on Myeloproliferative Disorders across 51 countries and 37 U.S. states, including 1,201 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent myeloid progenitor cells, most often caused by a mutation in the JAK2 protein tyrosine kinase.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Bone Marrow Diseases (4,084) and Narrower Categories: Acute Erythroblastic Leukemia (1,699), BCR-ABL Positive Chronic Myelogenous Leukemia (3,140), Chronic Neutrophilic Leukemia (287), Leukemoid Reaction (849), Myelophthisic Anemia (70), Polycythemia Vera (1,255), Primary Myelofibrosis (2,275), Thrombocytosis (2,602).
  4. Clinical Trials ClinicalTrials.gov : at least 531 including 29 Active, 286 Completed, 88 Recruiting


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Orazi, Attilio   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Pathology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.
    Physician  Highly Cited  Highly Published 
    Disclosed payments in 2021 from 2 biomedical companies, totalling $3,640, including $3,600 from  Novartis Pharmaceuticals Corporation
    Subjects: Bone Marrow; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Janus Kinase 2
    Categories: Pathology; Genetics; Diagnosis; Classification; Therapy; Standards
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016)
    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. (2018)

  2. Hasserjian, Robert P   Hematology   Google Publications
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Medical school: Harvard Medical School (MD, 1990)
    Medicare Accepted
    Subjects: Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Bone Marrow; Janus Kinase 2; Leukemia, Myeloid
    Categories: Genetics; Pathology; Classification; Diagnosis; Methods; Metabolism
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016)
    Myelodysplastic Syndrome Updated. (2019)

  3. Arber, Daniel A   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, University of Chicago, Chicago, Illinois, USA. Top Hospital
    Physician  Highly Cited  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.6/100
    Disclosed payments in 2021 from 8 biomedical companies, totalling $17,713, including $8,250 from  Astellas Pharma Global Development
    Subjects: Lymphoma; Bone Marrow; Bone Marrow Neoplasms; Bone Marrow Transplantation; Disease Models, Animal
    Categories: Genetics; Classification; Complications; Diagnosis; Adverse Effects; Pathology
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016)
    Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. (2018)

  4. Vardiman, James W   Clinical Pathology/Laboratory Medicine   Google Publications
    Department of Pathology, University of Chicago, Chicago, IL. Top Hospital
    Physician  Highly Cited 
    Subjects: Myelodysplastic Syndromes; Bone Marrow Neoplasms; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma
    Categories: Classification; Complications; Diagnosis; Genetics
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016)
    The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. (2010)

  5. Levine, Ross L   Hematology & Oncology   Google Publications
    Human Oncology and Pathogenesis Program and Leukemia service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Medical school: Johns Hopkins University School of Medicine (MD, 1999)
    Medicare Accepted
    Disclosed payments in 2021 from 15 biomedical companies, totalling $119,652.03, including $65,683.42 from  Qiagen, LLC
    Subjects: Janus Kinase 2; Mutation; Protein Kinase Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic
    Categories: Genetics; Metabolism; Antagonists & Inhibitors; Drug Therapy; Pharmacology; Pathology
    The role of mutations in epigenetic regulators in myeloid malignancies. (2012)
    Single-cell mutation analysis of clonal evolution in myeloid malignancies. (2020)

  6. Tefferi, Ayalew   Hematology   Google Publications
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Mutation; Myelodysplastic Syndromes; Janus Kinase 2; Primary Myelofibrosis; Bone Marrow Neoplasms
    Categories: Genetics; Diagnosis; Therapeutic Use; Therapy; Complications; Drug Therapy
    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. (2018)
    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. (2018)

  7. Mesa, Ruben A   Medical Oncology   ClinicalTrials.gov Google Publications
    Department of Hematology and Oncology, UT Health San Antonio MD Anderson Cancer Center, 7979 Wurzbach Rd, San Antonio, TX, 78229, USA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Review 
    Medical school: Other (MD, 1995)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 58/100
    Disclosed payments in 2021 from 26 biomedical companies, totalling $49,845.3, including $12,969.3 from  Incyte Corporation
    Subjects: Primary Myelofibrosis; Hematologic Neoplasms; Quality of Life; Janus Kinase 2; Protein Kinase Inhibitors
    Categories: Drug Therapy; Diagnosis; Therapy; Therapeutic Use; Epidemiology; Genetics
    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. (2018)
    Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. (2012)

  8. Verstovsek, Srdan   Medical Oncology   ClinicalTrials.gov Google Publications
    The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 51 biomedical companies, totalling $118,914.56, including $45,220.55 from  Incyte Corporation
    Subjects: Janus Kinase 2; Protein Kinase Inhibitors; Leukemia, Myeloid, Acute; Primary Myelofibrosis; Pyrazoles
    Categories: Genetics; Drug Therapy; Therapeutic Use; Antagonists & Inhibitors; Diagnosis; Pharmacology
    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. (2018)
    Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. (2010)

  9. Rampal, Raajit K   Medical Oncology   ClinicalTrials.gov Google Publications
    Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. . Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Clinical Trial 
    Disclosed payments in 2021 from 9 biomedical companies, totalling $12,795.5, including $5,265.5 from  Incyte Corporation
    Subjects: Janus Kinase 2; Leukemia, Myeloid, Acute; Antineoplastic Agents; Cell Transformation, Neoplastic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    Categories: Genetics; Metabolism; Drug Therapy; Therapeutic Use; Therapy; Complications
    Single-cell mutation analysis of clonal evolution in myeloid malignancies. (2020)
    Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. (2014)

  10. Borowitz, Michael J   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Pathology, John Hopkins Medical Institutions, Baltimore, MD;
    Physician 
    Disclosed payments in 2021 from 3 biomedical companies, totalling $1,064, including $973.5 from  Amgen Inc.
    Subjects: Hematopoietic Stem Cell Transplantation; Leukemia; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes
    Categories: Classification; Surgery
    The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (2016)
    NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. (2010)

  11. Kantarjian, Hagop M   Medical Oncology  Google Publications
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 23 biomedical companies, totalling $77,883.16, including $16,295 from  Amgen Inc.
    Subjects: Janus Kinase 2; Leukemia, Myeloid, Acute; Pyrazoles; Mutation; Protein Kinase Inhibitors
    Categories: Genetics; Drug Therapy; Therapeutic Use; Antagonists & Inhibitors; Blood; Administration & Dosage
    Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. (2010)
    Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. (2011)

  12. Ebert, Benjamin L   Hematology   Google Publications
    Division of Hematology, Brigham and Womens Hospital, Boston, MA 02115, USA. . Top Hospital
    Physician  Highly Cited 
    Subjects: Janus Kinase 2; Hematopoietic Stem Cells; STAT Transcription Factors; Amino Acid Substitution; Biomarkers, Tumor
    Categories: Genetics; Metabolism; Pathology; Physiology; Physiopathology; Antagonists & Inhibitors
    Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. (2018)
    Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. (2014)

  13. Talpaz, Moshe   Medical Oncology   Google Publications
    Department of Internal Medicine/Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI.
    Physician  Guideline 
    Medical school: Other (MD, 1975)
    Medicare Accepted
    Disclosed payments in 2021 from 6 biomedical companies, totalling $14,522, including $13,100 from  Novartis Pharmaceuticals Corporation
    Subjects: Primary Myelofibrosis; Calreticulin; Janus Kinase Inhibitors; Pyrrolidines; Receptors, Thrombopoietin
    Categories: Genetics; Therapeutic Use; Complications; Diagnosis; Drug Therapy; Etiology
    Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. (2021)
    NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. (2017)

  14. Maciejewski, Jaroslaw P   Hematology   Google Publications
    Department of Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, USA.
    Physician  Highly Cited  Highly Published 
    Medical school: Other (MD, 1990)
    Medicare Accepted
    Disclosed payments in 2021 from 11 biomedical companies, totalling $14,100.68, including $4,800 from  Celgene Corporation
    Subjects: Myelodysplastic Syndromes; Hematologic Neoplasms; Mutation; Anemia, Macrocytic; Biomarkers, Tumor
    Categories: Genetics; Diagnosis; Etiology; Therapy; Epidemiology; Standards
    Somatic SETBP1 mutations in myeloid malignancies. (2013)
    An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. (2015)

  15. Silver, Richard T   Medical Oncology   Google Publications
    Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA.
    Physician  Highly Cited  Guideline  Clinical Trial 
    Subjects: Cell Transformation, Neoplastic; Janus Kinase 2; Chromosomes, Human, Pair 1; Consensus; Endpoint Determination
    Categories: Genetics; Drug Therapy; Metabolism; Diagnosis; Methods; Pathology
    Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. (2018)
    TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. (2011)

  16. Wadleigh, Martha   Medical Oncology   Google Publications
    Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. Top Hospital
    Physician  Highly Cited  Guideline 
    Medical school: Duke University School of Medicine (MD, 1998)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 66/100
    Subjects: Blast Crisis; DNA-Binding Proteins; Enzyme Inhibitors; Extracellular Traps; Genomics
    Categories: Genetics; Metabolism; Diagnosis; Antagonists & Inhibitors; Classification; Drug Therapy
    Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. (2018)
    Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. (2014)

  17. Shih, Alan H   Medical Oncology  Google Publications
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Top Hospital
    Physician 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.4/100
    Subjects: Janus Kinase 2; Antineoplastic Agents; Epigenomics; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1
    Categories: Genetics; Administration & Dosage; Antagonists & Inhibitors; Drug Therapy; Metabolism; Pharmacology
    The role of mutations in epigenetic regulators in myeloid malignancies. (2012)
    CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. (2015)

  18. Pemmaraju, Naveen   Internal Medicine   ClinicalTrials.gov Google Publications
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 68/100
    Disclosed payments in 2021 from 18 biomedical companies, totalling $28,574.7, including $11,989.62 from  Stemline Therapeutics Inc.
    Subjects: Leukemia, Myeloid, Acute; Antineoplastic Agents; Protein Kinase Inhibitors; Janus Kinase 2; Social Media
    Categories: Genetics; Drug Therapy; Therapeutic Use; Pathology; Antagonists & Inhibitors; Diagnosis
    Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells. (2017)
    BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. (2017)

  19. Gotlib, Jason   Hematology   ClinicalTrials.gov Google Publications
    Division of Hematology, Stanford University School of Medicine and Stanford Cancer Institute, Stanford, CA. Top Hospital
    Physician  Highly Cited  Highly Published  Guideline  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 65/100
    Disclosed payments in 2021 from 7 biomedical companies, totalling $13,104.5, including $8,004.5 from  Blueprint Medicines Corporation
    Subjects: Eosinophilia; Janus Kinase 2; Mutation; Protein Kinase Inhibitors; Antineoplastic Agents
    Categories: Genetics; Therapeutic Use; Therapy; Complications; Diagnosis; Drug Therapy
    Myeloid neoplasms with eosinophilia. (2017)
    Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. (2010)

  20. Scadden, David T   Internal Medicine  Google Publications
    Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA. Top Hospital
    Physician 
    Disclosed payments from biomedical company (Agios Pharmaceuticals, Inc.) in 2021 for $16,250
    Subjects: Stem Cell Niche; Bone Marrow Cells; Bone Marrow Neoplasms; GTPase-Activating Proteins; Genes, Tumor Suppressor
    Categories: Genetics; Pathology; Deficiency; Etiology
    Xist RNA is a potent suppressor of hematologic cancer in mice. (2013)
    Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. (2012)

Note:
  1. These experts have limited publications on this topic in our database, so expertise assessment may not be accurate.
  2. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);